IMUC - ImmunoCellular Therapeutics, Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 3:48PM EDT
Stock chart is not supported by your current browser
Previous Close0.0190
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range0.0190 - 0.0190
52 Week Range0.0140 - 0.2694
Avg. Volume65,470
Market Cap796,765
Beta (3Y Monthly)3.51
PE Ratio (TTM)N/A
EPS (TTM)-0.2690
Earnings DateAug 24, 2017 - Aug 25, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • PR Newswire8 months ago

    ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

    LOS ANGELES, Oct. 17, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that on October 16, 2018, the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings to delist the Company's Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from the Exchange. Trading in the Company's securities on NYSE American has been suspended.

  • PR Newswire8 months ago

    ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

    LOS ANGELES, Oct. 15, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw its Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from listing on the NYSE American. ImmunoCellular intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with the Securities and Exchange Commission (the "SEC") on or about October 25, 2018.

  • PR Newswire10 months ago

    ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

    -Ongoing Exploration of Strategic Opportunities- -Continued Progress in Stem-to-T-Cell Program- LOS ANGELES , Aug. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ...

  • PR Newswire11 months ago

    ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit

    LOS ANGELES, July 19, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has reached an agreement in principle to settle the securities class action suit, filed on May 1, 2017 in the United States District Court for the Central District of California, captioned Arthur Kaye IRA FCC as Custodian DTD 6-8-00 v. ImmunoCellular Therapeutics, Ltd. et al., Case No. 2:17-cv-03250,  against the Company, certain of its current and former officers and directors, and others.

  • ACCESSWIRElast year

    Free Technical Research on ImmunoGen and Three More Biotech Equities

    On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).